NASDAQ$SYRE

Spyre Therapeutics Inc · Q1 2026 earnings

Q1 2026 earnings · · After market close · Investor relations

Briefing

Spyre Therapeutics Inc Q1 fiscal 2026: $69.0K net income, $0.74 loss per share

for the year ended December 31, 2025 (the “Annual Report”) as filed with the SEC on February 19, 2026.

  • Net income: $69.0K
  • Diluted EPS: $-0.74
  • Operating income: -45.6M

Headline financials

EPS (adj)

-$0.74

Previous: -$0.60-23.3%
Net Income

$69K

Previous: -$44.8M+100.2%
Operating Income

-$45.6M

Previous: -$53.6M+14.8%

Revenue & EPS history

Spyre · Revenue · Quarterly

$200M

Q3 2025
Beat estimate in 4 of 10 quarters(40%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

-0.4%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+2.3%

Avg return

30 days after

44%

17 / 39 earnings

Positive

+14.6%

Q4 2023

Best reaction

-10.9%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.6%+7.6%
Q3 2025+0.5%+4.6%+49.4%
Q1 2025-2.0%-0.7%+13.2%
Q4 2024+7.2%+6.0%-2.3%
Q3 2024+5.6%-4.4%-27.7%
Q2 2024-3.0%-6.6%+7.4%
Q1 2024+11.8%+19.0%+2.0%
Q4 2023+14.6%+44.3%+45.3%
Q3 2023-2.2%+10.8%+102.2%
Q2 2023-10.3%-12.0%+6.7%
Q1 2023-6.6%-9.1%-18.3%
Q4 2022-0.3%+2.0%-26.6%
Q3 2022-9.0%+3.7%-59.0%
Q2 2022+7.7%+5.9%+33.3%
Q1 2022-10.9%-5.8%-60.0%
Q4 2021+0.4%-14.6%+14.2%
Q3 2021-5.4%-5.8%-22.5%
Q2 2021-0.6%-3.3%+12.1%
Q1 2021+2.2%+4.4%-8.1%
Q4 2020+1.7%+9.7%+5.3%
Q3 2020+4.5%+22.1%+3.5%
Q2 2020-6.7%-4.7%+3.2%
Q1 2020+10.6%-4.5%+24.0%
Q4 2019-8.3%-13.2%-40.2%
Q3 2019-4.3%-2.2%-4.1%
Q2 2019-4.1%-3.8%-0.5%
Q1 2019-1.9%-2.1%-8.7%
Q4 2018-0.7%+3.1%+8.8%
Q3 2018+0.2%-13.0%-13.3%
Q2 2018+4.8%+1.2%-3.4%
Q1 2018+3.5%+0.6%+4.0%
Q4 2017-1.4%+23.7%+20.5%
Q3 2017-4.9%+4.5%+0.0%
Q2 2017-6.3%-7.2%+34.8%
Q1 2017-2.2%-2.0%-43.4%
Q4 2016-4.4%-6.9%-8.7%
Q3 2016-1.2%+1.3%-7.5%
Q2 2016+1.1%-1.9%+48.2%
Q1 2016+0.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro